Health tech entrepreneurs and their investors face high-stakes decisions under deep uncertainty. In this session, Luigi Negri draws on 20+ years in pharma and health technology innovation to present a decision-making methodology grounded in the scientific method. Drawing from his newly published Springer book,
De-Risking Investments in Medical Technology Innovation, he shares evidence from a comparative study showing that startups applying scientific rigor to business decisions actually move faster than those relying on intuition alone. The session explores how translational scientists can apply these principles as they consider entrepreneurial paths.
Learning Objectives:- Understand how the scientific method can be applied to business and investment decisions in health tech.
- Identify common failure modes in health tech startups and how evidence-based approaches mitigate risk.
- Reflect on the intersection of scientific training and entrepreneurial thinking in translational medicine careers.
